Skip to main content
Journal cover image

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

Publication ,  Journal Article
Leslie, KK; Filiaci, VL; Mallen, AR; Thiel, KW; Devor, EJ; Moxley, K; Richardson, D; Mutch, D; Secord, AA; Tewari, KS; McDonald, ME; Rose, PG ...
Published in: Gynecol Oncol
April 2021

BACKGROUND: Successfully combining targeted agents with chemotherapy is an important future goal for cancer therapy. However, an improvement in patient outcomes requires an enhanced understanding of the tumor biomarkers that predict for drug sensitivity. NRG Oncology/Gynecologic Oncology Group (GOG) Study GOG-86P was one of the first attempts to combine targeted agents (bevacizumab or temsirolimus) with chemotherapy in patients with advanced endometrial cancer. Herein we performed exploratory analyses to examine the relationship between mutations in TP53, the most commonly mutated gene in cancer, with outcomes on GOG-86P. METHODS: TP53 mutational status was determined and correlated with progression-free survival (PFS) and overall survival (OS) on GOG-86P. RESULTS: Mutations in TP53 were associated with improved PFS and OS for patients that received bevacizumab as compared to temsirolimus (PFS: HR 0.48, 95% CI 0.31, 0.75; OS: HR: 0.61, 95% CI 0.38, 0.98). By contrast, there was no statistically significant difference in PFS or OS between arms for cases with WT TP53. CONCLUSIONS: This exploratory study suggests that combining chemotherapy with bevacizumab, but not temsirolimus, may enhance PFS and OS for patients whose tumors harbor mutant p53. These data set the stage for larger clinical studies evaluating the potential of TP53 mutational status as a biomarker to guide choice of treatment for endometrial cancer patients. Clintrials.gov: NCT00977574.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

April 2021

Volume

161

Issue

1

Start / End Page

113 / 121

Location

United States

Related Subject Headings

  • Tumor Suppressor Protein p53
  • Treatment Outcome
  • Survival Rate
  • Sirolimus
  • Randomized Controlled Trials as Topic
  • Progression-Free Survival
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Recurrence, Local
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Leslie, K. K., Filiaci, V. L., Mallen, A. R., Thiel, K. W., Devor, E. J., Moxley, K., … Aghajanian, C. (2021). Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol, 161(1), 113–121. https://doi.org/10.1016/j.ygyno.2021.01.025
Leslie, Kimberly K., Virginia L. Filiaci, Adrianne R. Mallen, Kristina W. Thiel, Eric J. Devor, Katherine Moxley, Debra Richardson, et al. “Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.Gynecol Oncol 161, no. 1 (April 2021): 113–21. https://doi.org/10.1016/j.ygyno.2021.01.025.
Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, et al. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 Apr;161(1):113–21.
Leslie, Kimberly K., et al. “Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.Gynecol Oncol, vol. 161, no. 1, Apr. 2021, pp. 113–21. Pubmed, doi:10.1016/j.ygyno.2021.01.025.
Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 Apr;161(1):113–121.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

April 2021

Volume

161

Issue

1

Start / End Page

113 / 121

Location

United States

Related Subject Headings

  • Tumor Suppressor Protein p53
  • Treatment Outcome
  • Survival Rate
  • Sirolimus
  • Randomized Controlled Trials as Topic
  • Progression-Free Survival
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Recurrence, Local